Trump (R) announced on Friday, a Deal with Drugmaker AstraZeneca in His latest Effort to Lower Drug Costs through so-called “Most Favored Nation” Pricing.
The move comes after Trump Unveiled last week, an Agreement with Pfizer to Reduce Prices on Many of its Drugs, as Trump demanded in a July Letter to Pharmaceutical Company CEOs.
The Arrangement with AstraZeneca, One of Europe’s Largest Pharmaceutical Companies, is similar to the Pfizer Deal.
Both have Promised to Sell Drugs to Medicaid, and set Prices of New Medications at “Most Favored Nation” Levels, the Lowest Price made available inPpeer Countries.
They will Participate in the New TrumpRx Online Platform, which will become Operational in January 2026. The website will Direct Visitors to Drugmakers’ Direct-to-Consumer Channels, where their Products will be Available at a Discount to those willing to Pay Cash and forgo using Insurance.
AstraZeneca said in a Press Release about the Deal, that it will allow Eligible Patients with Prescriptions for Chronic Diseases to Purchase Drugs Directly at a Discount of up to 80% Off List Prices, which is the Cost before any Rebates or other Discounts.
Trump also pointed to AstraZeneca’s Promise to Spend $50 billion in Expanding its Manufacturing in the U.S., which it announced in July. The Company on Thursday unveiled a $4.5 billion Investment in Virginia, to Manufacture a Range of Medicines including Cancer Treatments.
NYC Wins When Everyone Can Vote! Michael H. Drucker
No comments:
Post a Comment